NatureWise Biotech & Medicals Corporation (NBM), a new drug development company founded in the year of 2000, focuses on the botanical drug and small molecule therapies. In order to strengthen research capabilities, new drug R&D center was established in 2004 located in the NanKang Biotech Incubation Center (NBIC) of the Ministry of Economic Affairs. Our first product, LipoCol Forte®, is the first traditional Chinese Medicine underwent clinical trial and approved by the Department of Health. Via collaborated with academic institutions, we invest in the development of therapeutic drugs for unmet medical needs. Several projects are in progress and will start the clinical trial.
By taking advantage of our profound knowledge in herbal medicines, we taken natural plants as the development target and started from the niche market to systematically develop the new value of natural plants. Based on the comprehensive evaluation on market, regulatory, and science, we draw up the best development strategies of drug candidates to be used in diseases in need of better treatment modalities.
R & D
NBM-BMX Oral Softgel Capsule
NBM-BMX Oral Softgel Capsule is a proprietary product developed by NatureWise Biotech & Medicals Corporation for the treatment of advanced cancer. The active pharmaceutical ingredient, NBM-BMX, is a new chemical entity with specific inhibition activity for histone deacetylase 8 (HDAC8). HADC family has various subtypes, which have different expression rates and biological functions are different. The development of isoform-selective HDAC inhibitors is becoming important in recent years due to the side effects observed in the FDA-approved non-selective HDAC inhibitors limiting their clinical application. HDAC8 plays an important role in tumor progression, their expression correlates with poor outcome in neuroblastoma and drives transcriptional plasticity in melanoma cells in response to a range of stresses. NBM-BMX exhibited superior safety and efficacy for tumor treatment, especially on those with high HDAC8 protein expression. The phase I clinical trial is ongoing in USA and Taiwan, and expected to be completed on Q4 2020.
LipoCol Forte® Capsule
LipoCol Forte® is the first traditional Chinese medicine underwent clinical trial in accordance with “Good Clinical Practice” and approved in Taiwan to lower cholesterol and triglyceride. LipoCol Forte® is derived from Monascus purpureus Went fermented on premium rice. The active constituent of LipoCol Forte® can inhibit HMG-CoA reductase, the rate-controlling enzyme in the cholesterol synthesis pathway. It is indicated for hypercholesterolemia and hypertriglyceridemia.
PPLs® Taiwan Green Propolis
PPLs® are a group of prenylflavanones with HDAC inhibitor activity isolated from Taiwan green propolis by a unique separation technology. NatureWise has undertaken studies of Taiwan green propolis for many years, and the study results received many patents and awards. PPLs® can increase the survival of neural stem cells, enhance the outgrowth of neurites, and modulate blood sugar.
The USFDA has reviewed and commented on the results of the phase 1 clinical trial of NBM-BMX and suggested changes on the draft clinical protocol of the phase 2 program
In 2018, in a letter approving the initiation of phase 1 clinical trials, the USFDA requested NatureWise schedule an end of phase 1 (EOP1) meeting with the FDA when NatureWise completed the phase 1 clinical program. In September 2021, NatureWise completed a phase 1 clinical trial in the USA, submitted the trial results to the USFDA along with a draft of the phase 2 [...]
NatureWise’s new chemical entity, NBM-MBX, received US Food and Drug Administration (FDA) approval on July 24th to proceed Phase I clinical trial. NBM-MBX is an isoform-selective histone deacetylase 8 (HDAC 8) inhibitor. The high specificity produces less side effects than those of non-selective HDAC inhibitors. […]